Oxidative stress and antioxidant status in prostate cancer patients: Relation to Gleason score, treatment and bone metastasis

Battisti, Vanessa; Maders, Liési D.K.; Bagatini, Margarete Dulce; Reetz, Luiz Gustavo Brenner; Chiesa, Juarez; Battisti, Iara Endruweit; Gonçalves, Jamile Fabbrin; Duarte, Marta Medeiros Frescura; Schetinger, Maria Rosa Chitolina; Morsch, Vera Maria

doi:10.1016/j.biopha.2011.06.003

Cited by 73 publications

(89 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent reports examined to demonstrate the possibility to using gamma-oryzanol to treat cancer including prostate cancer (Ng and Figg, 2003). The imbalance of oxidant-antioxidant system resulting in increased oxidative stress was reported as an important feature of this type of cancer (Battisti et al, 2011;Tangjitjaroenkun et al, 2012). The present study chose to assess the antioxidative effect of gamma-oryzanol on prostate cancer cell line, DU145 and PC3.…”

Section: Discussionmentioning

confidence: 99%

Antioxidant Effects of Gamma-oryzanol on Human Prostate Cancer Cells

Klongpityapong¹,

Supabphol²,

Supabphol³

2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: To assess the antioxidant effects of gamma-oryzanol on human prostate cancer cells. Materials and Methods: Cytotoxic activity of gamma-oryzanol on human DU145 and PC3 prostate cancer cells was determined by proliferation assay using 3-(4, 5-dimethylthiazol, 2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) reagent. mRNA levels of genes involved in the intracellular antioxidant system, superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPX) and glutathione reductase (GSR) were determined by reverse transcription-polymerase chain reaction (RT-PCR). Cancer cell lysates were used to measure lipid peroxidation using thiobarbituric acid reactive substance (TBARS). Glutathione contents of the cell lysates were estimated by the reaction between sulfhydryl group of 5, 5'-dithio (bis) nitrobenzoic acid (DTNB) to produce a yellowcolor of 5-thio-2-nitrobenzoic acid using colorimetric assay. Catalase activity was also analysed by examining peroxidative function. Protein concentration was estimated by Bradford's assay. Results: All concentrations of gamma-oryzanol, 0.1-2.0mg/ml, significantly inhibited cell growth in a dose-and time-dependent fashion in both prostate cancer cell lines, DU145 and PC3. Gene expression of catalase in DU145 and PC3 exposed to gamma-orizanol at 0.5mg/ml for 14 days was down regulated, while mRNA of GPX was also down regulated in PC3. The MDA and glutathione levels including catalase activity in the cell lysates of DU145 and PC3 treated with gamma-oryzanol 0.1 and 0.5mg/ml were generally decreased. Conclusions: This study highlighted effects of gamma-oryzanol via the down-regulation of antioxidant genes, catalase and GPX, not cytotoxic roles. This might be interesting for adjuvant chemotherapy to make prostate cancer cells more sensitive to free radicals. It might be useful for the reduction of cytotoxic agents and cancer chemoprevention.

show abstract

Section: Discussionmentioning

confidence: 99%

Antioxidant Effects of Gamma-oryzanol on Human Prostate Cancer Cells

Klongpityapong¹,

Supabphol²,

Supabphol³

2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Some authors demonstrated decreased activity while others showed no difference or increased activity. 21,[23][24][25] In their study, Biri et al reported increased CAT and GPx activity in PCa patients when compared with BPH and control. 25 They concluded that this increase was due to a rebound effect to increased oxidative stress in order to neutralize it.…”

Section: Discussionmentioning

confidence: 92%

Oxidative stress parameters in patients with prostate cancer, benign prostatic hyperplasia and asymptomatic inflammatory prostatitis: A prospective controlled study

Kaya¹,

Özgök²,

Zor³

et al. 2017

Adv Clin Exp Med

View full text Add to dashboard Cite

Background. The imbalance between oxidant and reductant mechanisms creates a nidus for the etiopathogenesis of several diseases. In this study, we aimed to compare the oxidative stress (OS) parameters in patients who were diagnosed with prostate cancer (pCa), benign prostatic hyperplasia (BPH) or asymptomatic inflammatory prostatitis (AIP), according to the histopathologic examination of transrectal ultrasonographic prostate biopsy and transurethral prostate resection specimens.

show abstract

“…On the other hand; in a different study, malignant epithelial cells in prostatic adenocarcinoma have been founded to express lower levels of antioxidant enzymes than does benign prostatic epithelium [27]. Battisti et al showed changes in oxidative stress biomarkers and antioxidant defenses parameters with having bone metastases or not, receiving treatment or not and gleason scores in patients with PCa [28]. Furthermore; in another study, it was founded a significant increase in oxidative stress group of patient those who were treated with androgen deprivation therapy and stated that antioxidant usage was preventing to progress to castration resistant prostate cancer stage [29].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Oxidative Stress Status and Antioxidant Capacity in Patients with Localized Prostate Cancer and Benign Prostatic Hyperplasia

Aldemir¹

2015

Ann Clin Anal Med

View full text Add to dashboard Cite

ÖzetAmaç: Bu çalışma, lokalize prostat kanseri (PCa) ve benign prostat hiperplazili (BPH) hastalarda oksidatif stres durumu ve antioksidan kapasitenin değer-lendirilmesi amacıyla yapılmıştır. Gereç ve Yöntem: Bu prospektif çalışmaya, tamamı histolojik tanılı 24 lokalize PCa ve 36 BPH'lı erkek hasta dahil edilmiştir. Lokalize PCa ve BPH tanılı hastaların sabah açlık kan örneklerinden, total oksidan durum (TOS), total antioksidan kapasite (TAC), paraoxonase1 (PON1), arylesterase ve total thiol düzeyleri araştırılmış ve karşılaştırılmış-tır. Bulgular: Hastaların ortalama yaşı BPH grubunda 67 ± 12 yıl, localize PCa grubunda ise 68 ± 8 yıl idi (p>0.05). Elde edilen verilere göre, tüm oksidatif stress parametreleri ve antioksidan kapasite değerleri açısından iki grup arasında istatistiksel anlamlı fark olmadığı tespit edilmiştir (tüm parametreler için p>0.05). Tartışma: Çalışmamızda elde ettiğimiz sonuçlara dayanarak, serumda çalışılan bu parametrelerin localize PCa ve BPH'lı hastaların ayırıcı tanısında bir belirteç olarak kullanılamayacağını göstermiştir. Anahtar KelimelerLokalize Prostat Kanseri; Oksidatif Stres; Antioksidan Kapasite Abstract Aim: The aim of this study was to evaluate the oxidative stress status and antioxidant capacity in patients with localized prostate cancer (PCa) and benign prostatic hyperplasia (BPH). Material and Method: The prospective study consisting 24 men with PCa and 36 men with BPH. PCa or BPH were diagnosed histologically. Blood samples were obtained following an overnight fasting state. We evaluated and compared the total oxidant status (TOS), total antioxidant capacity (TAC), paraoxonase1 (PON1), arylesterase and total thiol levels of patients with PCa and BPH. Results: The mean age of BPH group was 67 ± 12 years and PCa group was 63 ± 8 years (p>0.05). No statistically significant differences were detected between the groups in terms of oxidative stress parameters and antioxidant capacity measured in the serum of patients including PON1, TOS, TAC, arylesterase and thiols levels (p>0.05 for all parameters). Discussion: Our results demonstrated that evaluation of these parameters in the serum of BPH and localized PCa patients may not be used as a marker to discriminate between these diseases.

show abstract

Oxidative stress and antioxidant status in prostate cancer patients: Relation to Gleason score, treatment and bone metastasis

Cited by 73 publications

References 44 publications

Antioxidant Effects of Gamma-oryzanol on Human Prostate Cancer Cells

Antioxidant Effects of Gamma-oryzanol on Human Prostate Cancer Cells

Oxidative stress parameters in patients with prostate cancer, benign prostatic hyperplasia and asymptomatic inflammatory prostatitis: A prospective controlled study

Evaluation of Oxidative Stress Status and Antioxidant Capacity in Patients with Localized Prostate Cancer and Benign Prostatic Hyperplasia

Contact Info

Product

Resources

About